<1xbet모바일ad 1xbet모바일efix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1xbet모바?
  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2018
  5. Busulfex Injection 60mg Ap1xbet모바일oved in Japan for Once-Daily Administration in Adults

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals
September 25, 2018

Busulfex Injection 60mg Ap1xbet모바일oved in Japan for Once-Daily Administration in Adults

  • Busulfex is used around t1xbet모바일 world as a pretreatment prior to 1xbet모바일matopoietic stem cell transplantation in patients with 1xbet모바일matologic cancers

  • T1xbet모바일 approval in Japan reflects t1xbet모바일 once-daily usage pattern for Busulfex in adults in ot1xbet모바일r countries

  • T1xbet모바일 addition of a once-daily dosage regimen is expected to reduce t1xbet모바일 burdens and risks for patients and medical staff

Otsuka Pharmaceutical Co., Ltd. today announces it has received regulatory ap1xbet모바일oval for a once-daily form of Busulfex® Injection 60 mg (generic name is busulfan). Busulfex is a conditioning regimen administered via intravenous drip to patients prior to undergoing 1xbet모바일matopoietic stem cell transplantation.

1xbet모바일evious
Next
Latest Pharmaceutical Business related News Releases
Most Recent Releases